Rosetta Genomics Passes California, Rhode Island, and Maryland CLIA Certification; Files 2008 Audited Financial Statements on Form 6-K

PHILADELPHIA & REHOVOT, Israel--(BUSINESS WIRE)--Rosetta Genomics, Ltd. (NASDAQ: ROSG) an innovative molecular diagnostic company leveraging microRNAs as biomarkers, today announced that its Philadelphia-based laboratory has passed the survey for CLIA (Clinical Laboratory Improvement Amendments) certification in California, Rhode Island and Maryland. This brings the number of states permitting commercial molecular diagnostics tests at Rosetta Laboratories to 48. Rosetta also announces that on June 11^th it filed its audited financial statements with the U.S. Securities and Exchange Commission on Form 6-K. The financial statements provide additional information with respect to the terms of the license and collaboration agreement with Prometheus Laboratories, including the potential for Rosetta to receive up to $17 million in research and development, milestone and other payments in addition to royalties on the sale of the tests.

Amir Avniel, president and chief executive officer of Rosetta said, “We have been making excellent progress in our goal to become a fully commercialized molecular diagnostics company. The addition of California, Rhode Island, and Maryland to the list of states in which Rosetta Laboratories is able to market its tests is an important achievement.”

About Rosetta Genomics

Rosetta Genomics is a leading molecular diagnostics company developing and commercializing molecular diagnostic products based on its proprietary microRNAs. Rosetta Genomics is working to develop early detection cancer screening products, including a colon cancer screening test. Rosetta performs its commercial molecular diagnostics tests at Rosetta Genomics Laboratories in Philadelphia.

About MicroRNAs

MicroRNAs (miRNAs) are recently discovered, naturally occurring, small RNAs that act as master regulators and have the potential to form the basis for a new class of diagnostics and therapeutics. Since many diseases are caused by the abnormal activity of proteins, the ability to selectively regulate protein activity through microRNAs could provide the means to treat a wide range of human diseases. In addition, microRNAs have been shown to have different expression in various pathological conditions. As a result, these differences may provide for a novel diagnostic and therapeutic strategy for many diseases.

Forward-Looking Statements

Various statements in this release concerning Rosetta’s future expectations, plans and prospects, including without limitation, statements relating to the role of microRNAs in human physiology and disease, the potential of microRNAs in the development of therapeutics and diagnostic products, constitute forward-looking statements for the purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Actual results may differ materially from those indicated by these forward-looking statements as a result of various important factors, including those risks more fully discussed under “Key Information - Risk Factors” in Rosetta’s Annual Report on Form 20-F for the year ended December 31, 2007 on file with the Securities and Exchange Commission. In addition, any forward-looking statements represent Rosetta’s views only as of today and should not be relied upon as representing its views as of any subsequent date. Rosetta does not assume any obligation to update any forward-looking statements unless required by law.

Company Contact:
Rosetta Genomics
Ron Kamienchick, 646-509-1893
investors@rosettagenomics.com
or
Investor Contacts:
Lippert/Heilshorn & Associates
Kim Sutton Golodetz, 212-838-3777
kgolodetz@lhai.com
or
Bruce Voss, 310-691-7100
bvoss@lhai.com